TLR7 ligand (SZU101) prevents PRRSV replication in PAMs.
SZU101 treatment activates NF-κB and induces antiviral cytokines and genes expression.
Blocking the activation of NF-κB reverses the suppression effect of SZU101 on PRRSV replication.
Inhibiting the proper subcellular localization of TLR7 using specific inhibitor reverses the anti-PRRSV effect of SZU101.
Co-administration of SZU101 and PRRSV enhances the humoral and cellular immune responses against PRRSV antigens in mice.